A5101425808- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Liver Disease Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Neutropenia and Cancer Infections
- Cardiac Arrhythmias and Treatments
- Nausea and vomiting management
- Airway Management and Intubation Techniques
- Neuroblastoma Research and Treatments
- Trauma Management and Diagnosis
- Musculoskeletal pain and rehabilitation
- Myofascial pain diagnosis and treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Nitric Oxide and Endothelin Effects
- Diet, Metabolism, and Disease
- Medical and Biological Ozone Research
- Vascular Tumors and Angiosarcomas
- Alcohol Consumption and Health Effects
- Cancer Mechanisms and Therapy
- Semiconductor materials and interfaces
- Organic and Molecular Conductors Research
Weatherford College
2024
Saitama Medical University
2010-2024
Saitama International Medical Center
2024
Hirosaki National Hospital
2004-2018
The University of Tokyo
2010-2011
Imperial College London
2010
Inserm
2010
ESPCI Paris
2010
Centre National de la Recherche Scientifique
2010
ParisTech
2010
Journal Article Complete remission of metastatic clear cell sarcoma with DAV chemotherapy Get access M. Fujimoto, Fujimoto Department Dermatology, Jichi Medical School, Minami‐Kawachi‐machi, Japan 329‐0498, Tochigi, Japan. Tel.: +81 285 58 7360. Fax: 44 4857. E‐mail: dermat@jichi.ac.jp Search for other works by this author on: Oxford Academic Google Scholar Hiraga, Hiraga T. Kiyosawa, Kiyosawa T Murakami, Murakami S. Murata, Murata Ohtsuki, Ohtsuki H. Nakagawa Clinical and Experimental...
Abstract Purpose: The purpose of this study was to determine the effectiveness Arthrokinematic Approach (AKA)-Hakata method for patients with low back pain (LBP). Methods: subjects were 39 LBP who visited a medical facility between June 1, 2022 and November 30, 2022. intervention period 8 weeks 5 treatment sessions, patient assessments performed using self-reported majors motor function assessment. Results: AKA-Hakata showed significant differences in all items evaluated longitudinal...
[Purpose] This study aimed to determine the effectiveness of Arthrokinematic Approach (AKA)-Hakata method for patients with low back pain (LBP). [Participants and Methods] The participants were 39 LBP who visited a medical facility between June 1, 2022, November 30, 2022. intervention period was 8 weeks, five treatment sessions, patient assessments performed using self-reported measures motor function assessment. [Results] AKA-Hakata showed significant differences in all items evaluated...
7333 Background: The purpose of this study was to determine maximum tolerated dose (MTD) a combination GEM plus CBDCA administration on biweekly schedule for inoperable NSCLC, and assess the efficacy safety at that recommended (RD). Methods: Patients with stage IIIB IV NSCLC included in were treated followed by GEM. given intravenously over 30 minutes, minutes. Treatment repeated every 2 weeks. Results: Three patients enrolled level 1 (CBDCA AUC=2 800 mg/m2), 3 1000 AUC=2.5 mg/m2) 6 4 AUC=3...
7237 Background: The purpose of this study was to determine maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) a combination gemcitabine plus carboplatin administration in biweekly schedule for inoperable NSCLC. Methods: Patients with stages IIIB IV NSCLC included were treated followed by gemcitabine. Carboplatin given intravenously over 30 minutes, minutes. Results: Fifteen patients at 4 levels. As DLT, treatment delay occurred level 2 6 patients. No DLT experienced levels 1,...
4055 Background: Ten years have passed since radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) was introduced at the authors’ institution. The aim of this study to elucidate long-term efficacy RFA in a large series from single center. Methods: We enrolled all patients with HCC who underwent hospital between 1999 and 2008. primary endpoint overall survival. Secondary time recurrence safety. assessed survival as initial treatment (n = 1,030), showed complete response 999),...